Inovio Pharmaceuticals, Inc. (INO) announced today that it has completed enrollment in the company’s open-label, 24 patient, Phase 2 trial with its lead immunotherapy product VGX-3100 in patients with precancerous lesions of the anus, i.e. anal high-grade...
As summer winds its way to an end, biopharmaceutical companies continue to conduct clinical trials and release news related to them. Here’s a look at last week’s clinical trial headlines. Oncologie and Merck will launch a Phase II trial to investigate Merck’s Keytruda...
Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced the dosing of the first patient in AKST6021-211, a phase 2 clinical trial of its proprietary human plasma fraction,...
– ActoBio Therapeutics, Inc., a wholly owned subsidiary of Intrexon Corporation (NASDAQ: XON) and innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents, announced that the U.S. Food and Drug Administration...
Trial will evaluate the effectiveness of perivascular sirolimus to improve AV Fistula outcomes in patients with kidney disease Vascular Therapies, a biotechnology company focused on improving vascular access outcomes in patients with kidney disease, today announced...
Henry Ford Cancer Institute first to put patient in GBM Agile Trial, which aims to identify most effective therapies for patients with glioblastoma August 15, 2019 — Henry Ford Cancer Institute is first-in-the-world to enroll a glioblastoma patient in the GBM AGILE...
Email
Text